{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T22:18:26Z","timestamp":1792448306224,"version":"4.5.0"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"8015","license":[{"start":{"date-parts":[[2024,5,8]],"date-time":"2024-05-08T00:00:00Z","timestamp":1715126400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,5,8]],"date-time":"2024-05-08T00:00:00Z","timestamp":1715126400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nature"],"published-print":{"date-parts":[[2024,6,6]]},"DOI":"10.1038\/s41586-024-07403-2","type":"journal-article","created":{"date-parts":[[2024,5,8]],"date-time":"2024-05-08T12:02:58Z","timestamp":1715169778000},"page":"237-246","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":85,"title":["Structural pharmacology and therapeutic potential of 5-methoxytryptamines"],"prefix":"10.1038","volume":"630","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1538-8648","authenticated-orcid":false,"given":"Audrey L.","family":"Warren","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1210-5673","authenticated-orcid":false,"given":"David","family":"Lankri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Cunningham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3588-821X","authenticated-orcid":false,"given":"Inis C.","family":"Serrano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7527-8977","authenticated-orcid":false,"given":"Lyonna F.","family":"Parise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew C.","family":"Kruegel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9728-282X","authenticated-orcid":false,"given":"Priscilla","family":"Duggan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory","family":"Zilberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0102-6993","authenticated-orcid":false,"given":"Michael J.","family":"Capper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6911-4669","authenticated-orcid":false,"given":"Vaclav","family":"Havel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6470-1805","authenticated-orcid":false,"given":"Scott J.","family":"Russo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6911-2260","authenticated-orcid":false,"given":"Dalibor","family":"Sames","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4951-7230","authenticated-orcid":false,"given":"Daniel","family":"Wacker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,8]]},"reference":[{"key":"7403_CR1","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1007\/s00213-017-4771-x","volume":"235","author":"RL Carhart-Harris","year":"2018","unstructured":"Carhart-Harris, R. L. et al. Psilocybin with psychological support for treatment-resistant depression: six-month follow-up. Psychopharmacology\u00a0235, 399\u2013408 (2018).","journal-title":"Psychopharmacology"},{"key":"7403_CR2","doi-asserted-by":"publisher","unstructured":"Armstrong, S. B. et al. Prospective associations of psychedelic treatment for co-occurring alcohol misuse and posttraumatic stress symptoms among United States Special Operations Forces veterans. Mil. Psychol. https:\/\/doi.org\/10.1080\/08995605.2022.2156200 (2023).","DOI":"10.1080\/08995605.2022.2156200"},{"key":"7403_CR3","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1056\/NEJMoa2206443","volume":"387","author":"GM Goodwin","year":"2022","unstructured":"Goodwin, G. M. et al. Single-dose psilocybin for a treatment-resistant episode of major depression. N. Engl. J. Med. 387, 1637\u20131648 (2022).","journal-title":"N. Engl. J. Med."},{"key":"7403_CR4","doi-asserted-by":"publisher","unstructured":"Cameron, L. P. et al. 5-HT2ARs mediate therapeutic behavioral effects of psychedelic tryptamines. ACS Chem. Neurosci. https:\/\/doi.org\/10.1021\/acschemneuro.2c00718 (2023).","DOI":"10.1021\/acschemneuro.2c00718"},{"key":"7403_CR5","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/s00213-006-0566-1","volume":"189","author":"K Krebs-Thomson","year":"2006","unstructured":"Krebs-Thomson, K., Ruiz, E. M., Masten, V., Buell, M. & Geyer, M. A. The roles of 5-HT1A and 5-HT2 receptors in the effects of 5-MeO-DMT on locomotor activity and prepulse inhibition in rats. Psychopharmacology 189, 319\u2013329 (2006).","journal-title":"Psychopharmacology"},{"key":"7403_CR6","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1093\/jat\/bkab038","volume":"46","author":"HM Schwelm","year":"2022","unstructured":"Schwelm, H. M. et al. Qualitative and quantitative analysis of tryptamines in the poison of Incilius alvarius (Amphibia: Bufonidae). J. Anal. Toxicol. 46, 540\u2013548 (2022).","journal-title":"J. Anal. Toxicol."},{"key":"7403_CR7","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.ejphar.2005.01.018","volume":"510","author":"ZA Hughes","year":"2005","unstructured":"Hughes, Z. A. et al. Neurochemical evaluation of the novel 5-HT1A receptor partial agonist\/serotonin reuptake inhibitor, vilazodone. Eur. J. Pharmacol. 510, 49\u201357 (2005).","journal-title":"Eur. J. Pharmacol."},{"key":"7403_CR8","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.brainres.2012.04.032","volume":"1461","author":"C Loane","year":"2012","unstructured":"Loane, C. & Politis, M. Buspirone: what is it all about? Brain Res. 1461, 111\u2013118 (2012).","journal-title":"Brain Res."},{"key":"7403_CR9","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/S0091-3057(99)00178-1","volume":"65","author":"JC Winter","year":"2000","unstructured":"Winter, J. C., Filipink, R. A., Timineri, D., Helsley, S. E. & Rabin, R. A. The paradox of 5-methoxy-N,N-dimethyltryptamine: an indoleamine hallucinogen that induces stimulus control via 5-HT1A receptors. Pharmacol. Biochem. Behav. 65, 75\u201382 (2000).","journal-title":"Pharmacol. Biochem. Behav."},{"key":"7403_CR10","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1080\/00952990.2018.1545024","volume":"45","author":"AK Davis","year":"2019","unstructured":"Davis, A. K., So, S., Lancelotta, R., Barsuglia, J. P. & Griffiths, R. R. 5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) used in a naturalistic group setting is associated with unintended improvements in depression and anxiety. Am. J. Drug Alcohol Abuse 45, 161\u2013169 (2019).","journal-title":"Am. J. Drug Alcohol Abuse"},{"key":"7403_CR11","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1111\/jnc.15587","volume":"162","author":"JT Reckweg","year":"2022","unstructured":"Reckweg, J. T. et al. The clinical pharmacology and potential therapeutic applications of 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT). J. Neurochem. 162, 128\u2013146 (2022).","journal-title":"J. Neurochem."},{"key":"7403_CR12","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.2147\/NDT.S279342","volume":"18","author":"M Chauhan","year":"2022","unstructured":"Chauhan, M., Parry, R. & Bobo, W. V. Vilazodone for major depression in adults: pharmacological profile and an updated review for clinical practice. Neuropsychiatr. Dis. Treat. 18, 1175\u20131193 (2022).","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"7403_CR13","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1016\/j.cell.2020.08.024","volume":"182","author":"K Kim","year":"2020","unstructured":"Kim, K. et al. Structure of a hallucinogen-activated Gq-coupled 5-HT2A serotonin receptor. Cell 182, 1574\u20131588.e19 (2020).","journal-title":"Cell"},{"key":"7403_CR14","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.cell.2016.12.033","volume":"168","author":"D Wacker","year":"2017","unstructured":"Wacker, D. et al. Crystal structure of an LSD-bound human serotonin receptor. Cell 168, 377\u2013389.e12 (2017).","journal-title":"Cell"},{"key":"7403_CR15","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1038\/s41586-020-3008-z","volume":"589","author":"LP Cameron","year":"2021","unstructured":"Cameron, L. P. et al. A non-hallucinogenic psychedelic analogue with therapeutic potential. Nature 589, 474\u2013479 (2021).","journal-title":"Nature"},{"key":"7403_CR16","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1038\/s41586-022-05258-z","volume":"610","author":"AL Kaplan","year":"2022","unstructured":"Kaplan, A. L. et al. Bespoke library docking for 5-HT2A receptor agonists with antidepressant activity. Nature 610, 582\u2013591 (2022).","journal-title":"Nature"},{"key":"7403_CR17","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1177\/0269881117725915","volume":"31","author":"RL Carhart-Harris","year":"2017","unstructured":"Carhart-Harris, R. L. & Nutt, D. J. Serotonin and brain function: a tale of two receptors. J. Psychopharmacol. 31, 1091\u20131120 (2017).","journal-title":"J. Psychopharmacol."},{"key":"7403_CR18","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1038\/s41589-020-0535-8","volume":"16","author":"RHJ Olsen","year":"2020","unstructured":"Olsen, R. H. J. et al. TRUPATH, an open-source biosensor platform for interrogating the GPCR transducerome. Nat. Chem. Biol. 16, 841\u2013849 (2020).","journal-title":"Nat. Chem. Biol."},{"key":"7403_CR19","first-page":"1","volume":"36","author":"DE Nichols","year":"2018","unstructured":"Nichols, D. E. Chemistry and structure\u2013activity relationships of psychedelics. Curr. Top. Behav. Neurosci. 36, 1\u201343 (2018).","journal-title":"Curr. Top. Behav. Neurosci."},{"key":"7403_CR20","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S0376-8716(99)00148-9","volume":"60","author":"RA Glennon","year":"2000","unstructured":"Glennon, R. A. et al. Binding of \u03b2-carbolines and related agents at serotonin (5-HT2 and 5-HT1A), dopamine (D2) and benzodiazepine receptors. Drug Alcohol Depend. 60, 121\u2013132 (2000).","journal-title":"Drug Alcohol Depend."},{"key":"7403_CR21","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.neuropharm.2011.01.017","volume":"61","author":"AL Halberstadt","year":"2011","unstructured":"Halberstadt, A. L. & Geyer, M. A. Multiple receptors contribute to the behavioral effects of indoleamine hallucinogens. Neuropharmacology 61, 364\u2013381 (2011).","journal-title":"Neuropharmacology"},{"key":"7403_CR22","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1038\/s41586-021-03376-8","volume":"592","author":"P Xu","year":"2021","unstructured":"Xu, P. et al. Structural insights into the lipid and ligand regulation of serotonin receptors. Nature 592, 469\u2013473 (2021).","journal-title":"Nature"},{"key":"7403_CR23","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/S1043-9471(05)80049-7","volume":"25","author":"JA Ballesteros","year":"1995","unstructured":"Ballesteros, J. A. & Weinstein, H. Integrated methods for the construction of three-dimensional models and computational probing of structure\u2013function relations in G protein-coupled receptors. Methods Neurosci. 25, 366\u2013428 (1995).","journal-title":"Methods Neurosci."},{"key":"7403_CR24","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1038\/nature10361","volume":"477","author":"SG Rasmussen","year":"2011","unstructured":"Rasmussen, S. G. et al. Crystal structure of the \u03b22 adrenergic receptor\u2013Gs protein complex. Nature 477, 549\u2013555 (2011).","journal-title":"Nature"},{"key":"7403_CR25","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1126\/science.1232808","volume":"340","author":"D Wacker","year":"2013","unstructured":"Wacker, D. et al. Structural features for functional selectivity at serotonin receptors. Science 340, 615\u2013619 (2013).","journal-title":"Science"},{"key":"7403_CR26","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/0166-4328(96)00080-0","volume":"73","author":"DE Nichols","year":"1996","unstructured":"Nichols, D. E., Monte, A., Huang, X. & Marona-Lewicka, D. Stereoselective pharmacological effects of lysergic acid amides possessing chirality in the amide substituent. Behav. Brain Res. 73, 117\u2013119 (1996).","journal-title":"Behav. Brain Res."},{"key":"7403_CR27","doi-asserted-by":"publisher","first-page":"6208","DOI":"10.1021\/ja01652a113","volume":"76","author":"ME Speeter","year":"1954","unstructured":"Speeter, M. E. & Anthony, W. C. The action of oxalyl chloride on indoles\u2014a new approach to tryptamines. J. Am. Chem. Soc. 76, 6208\u20136210 (1954).","journal-title":"J. Am. Chem. Soc."},{"key":"7403_CR28","unstructured":"Shulgin, A. T. & Shulgin, A. Tihkal: The Continuation (Transform Press, 1997)."},{"key":"7403_CR29","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1124\/jpet.122.001454","volume":"385","author":"LB Kozell","year":"2023","unstructured":"Kozell, L. B. et al. Pharmacologic activity of substituted tryptamines at 5-hydroxytryptamine (5-HT)2A receptor (5-HT2AR), 5-HT2CR, 5-HT1AR, and serotonin transporter. J. Pharmacol. Exp. Ther. 385, 62\u201375 (2023).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"7403_CR30","doi-asserted-by":"publisher","first-page":"4701","DOI":"10.1021\/jm000339w","volume":"43","author":"JB Blair","year":"2000","unstructured":"Blair, J. B. et al. Effect of ring fluorination on the pharmacology of hallucinogenic tryptamines. J. Med. Chem. 43, 4701\u20134710 (2000).","journal-title":"J. Med. Chem."},{"key":"7403_CR31","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/S0960-894X(01)00062-2","volume":"11","author":"U Laban","year":"2001","unstructured":"Laban, U., Kurrasch-Orbaugh, D., Marona-Lewicka, D. & Nichols, D. E. A novel fluorinated tryptamine with highly potent serotonin 5-HT1A receptor agonist properties. Bioorg. Med. Chem. Lett. 11, 793\u2013795 (2001).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"7403_CR32","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1126\/science.1232807","volume":"340","author":"C Wang","year":"2013","unstructured":"Wang, C. et al. Structural basis for molecular recognition at serotonin receptors. Science 340, 610\u2013614 (2013).","journal-title":"Science"},{"key":"7403_CR33","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1177\/0269881114555249","volume":"29","author":"P Gasser","year":"2015","unstructured":"Gasser, P., Kirchner, K. & Passie, T. LSD-assisted psychotherapy for anxiety associated with a life-threatening disease: a qualitative study of acute and sustained subjective effects. J. Psychopharmacol. 29, 57\u201368 (2015).","journal-title":"J. Psychopharmacol."},{"key":"7403_CR34","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1177\/0269881110388326","volume":"25","author":"AL Halberstadt","year":"2011","unstructured":"Halberstadt, A. L., Koedood, L., Powell, S. B. & Geyer, M. A. Differential contributions of serotonin receptors to the behavioral effects of indoleamine hallucinogens in mice. J. Psychopharmacol. 25, 1548\u20131561 (2011).","journal-title":"J. Psychopharmacol."},{"key":"7403_CR35","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1016\/0091-3057(90)90098-3","volume":"36","author":"NA Darmani","year":"1990","unstructured":"Darmani, N. A., Martin, B. R., Pandey, U. & Glennon, R. A. Do functional relationships exist between 5-HT1A and 5-HT2 receptors. Pharmacol. Biochem. Behav. 36, 901\u2013906 (1990).","journal-title":"Pharmacol. Biochem. Behav."},{"key":"7403_CR36","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/0014-2999(89)90178-7","volume":"161","author":"J Arnt","year":"1989","unstructured":"Arnt, J. & Hyttel, J. Facilitation of 8-OHDPAT-induced forepaw treading of rats by the 5-HT2 agonist DOI. Eur. J. Pharmacol. 161, 45\u201351 (1989).","journal-title":"Eur. J. Pharmacol."},{"key":"7403_CR37","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1177\/02698811211050543","volume":"36","author":"AO Ermakova","year":"2022","unstructured":"Ermakova, A. O., Dunbar, F., Rucker, J. & Johnson, M. W. A narrative synthesis of research with 5-MeO-DMT. J. Psychopharmacol. 36, 273\u2013294 (2022).","journal-title":"J. Psychopharmacol."},{"key":"7403_CR38","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.biopsych.2016.06.012","volume":"81","author":"RC Bagot","year":"2017","unstructured":"Bagot, R. C. et al. Ketamine and imipramine reverse transcriptional signatures of susceptibility and induce resilience-specific gene expression profiles. Biol. Psychiatry 81, 285\u2013295 (2017).","journal-title":"Biol. Psychiatry"},{"key":"7403_CR39","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1126\/science.1120972","volume":"311","author":"O Berton","year":"2006","unstructured":"Berton, O. et al. Essential role of BDNF in the mesolimbic dopamine pathway in social defeat stress. Science 311, 864\u2013868 (2006).","journal-title":"Science"},{"key":"7403_CR40","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/j.biopsych.2013.12.014","volume":"76","author":"RJ Donahue","year":"2014","unstructured":"Donahue, R. J., Muschamp, J. W., Russo, S. J., Nestler, E. J. & Carlezon, W. A. Jr. Effects of striatal \u0394FosB overexpression and ketamine on social defeat stress-induced anhedonia in mice. Biol. Psychiatry 76, 550\u2013558 (2014).","journal-title":"Biol. Psychiatry"},{"key":"7403_CR41","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1038\/nprot.2011.361","volume":"6","author":"SA Golden","year":"2011","unstructured":"Golden, S. A., Covington, H. E. 3rd, Berton, O. & Russo, S. J. A standardized protocol for repeated social defeat stress in mice. Nat. Protoc. 6, 1183\u20131191 (2011).","journal-title":"Nat. Protoc."},{"key":"7403_CR42","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.cell.2007.09.018","volume":"131","author":"V Krishnan","year":"2007","unstructured":"Krishnan, V. et al. Molecular adaptations underlying susceptibility and resistance to social defeat in brain reward regions. Cell 131, 391\u2013404 (2007).","journal-title":"Cell"},{"key":"7403_CR43","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1007\/BF00187257","volume":"93","author":"P Willner","year":"1987","unstructured":"Willner, P., Towell, A., Sampson, D., Sophokleous, S. & Muscat, R. Reduction of sucrose preference by chronic unpredictable mild stress, and its restoration by a tricyclic antidepressant. Psychopharmacology 93, 358\u2013364 (1987).","journal-title":"Psychopharmacology"},{"key":"7403_CR44","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1016\/j.biopsych.2010.12.015","volume":"69","author":"N Li","year":"2011","unstructured":"Li, N. et al. Glutamate N-methyl-d-aspartate receptor antagonists rapidly reverse behavioral and synaptic deficits caused by chronic stress exposure. Biol. Psychiatry 69, 754\u2013761 (2011).","journal-title":"Biol. Psychiatry"},{"key":"7403_CR45","doi-asserted-by":"publisher","unstructured":"Hesselgrave, N., Troppoli, T. A., Wulff, A. B., Cole, A. B. & Thompson, S. M. Harnessing psilocybin: antidepressant-like behavioral and synaptic actions of psilocybin are independent of 5-HT2R activation in mice. Proc. Natl Acad. Sci. USA https:\/\/doi.org\/10.1073\/pnas.2022489118 (2021).","DOI":"10.1073\/pnas.2022489118"},{"key":"7403_CR46","doi-asserted-by":"publisher","first-page":"2535","DOI":"10.1016\/j.neuron.2021.06.008","volume":"109","author":"LX Shao","year":"2021","unstructured":"Shao, L. X. et al. Psilocybin induces rapid and persistent growth of dendritic spines in frontal cortex in vivo. Neuron 109, 2535\u20132544.e4 (2021).","journal-title":"Neuron"},{"key":"7403_CR47","doi-asserted-by":"publisher","first-page":"109836","DOI":"10.1016\/j.celrep.2021.109836","volume":"37","author":"M de la Fuente Revenga","year":"2021","unstructured":"de la Fuente Revenga, M. et al. Prolonged epigenomic and synaptic plasticity alterations following single exposure to a psychedelic in mice. Cell Rep. 37, 109836 (2021).","journal-title":"Cell Rep."},{"key":"7403_CR48","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.tins.2020.11.008","volume":"44","author":"NK Savalia","year":"2021","unstructured":"Savalia, N. K., Shao, L. X. & Kwan, A. C. A dendrite-focused framework for understanding the actions of ketamine and psychedelics. Trends Neurosci. 44, 260\u2013275 (2021).","journal-title":"Trends Neurosci."},{"key":"7403_CR49","doi-asserted-by":"publisher","unstructured":"Bickle, J. G. et al. 5HT1A receptors on dentate gyrus granule cells confer stress resilience. Biol. Psychiatry https:\/\/doi.org\/10.1016\/j.biopsych.2023.10.007 (2023).","DOI":"10.1016\/j.biopsych.2023.10.007"},{"key":"7403_CR50","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.brainres.2018.03.016","volume":"1688","author":"A Newman-Tancredi","year":"2018","unstructured":"Newman-Tancredi, A. et al. NLX-112, a highly selective 5-HT1A receptor agonist, mediates analgesia and antidepressant-like activity in rats via spinal cord and prefrontal cortex 5-HT1A receptors, respectively. Brain Res. 1688, 1\u20137 (2018).","journal-title":"Brain Res."},{"key":"7403_CR51","doi-asserted-by":"publisher","unstructured":"Becker, A. M. et al. Ketanserin reverses the acute response to LSD in a randomized, double-blind, placebo-controlled, crossover study in healthy subjects. Int. J. Neuropsychopharmacol. https:\/\/doi.org\/10.1093\/ijnp\/pyac075 (2022).","DOI":"10.1093\/ijnp\/pyac075"},{"key":"7403_CR52","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/0166-4328(96)00081-2","volume":"73","author":"RJ Strassman","year":"1996","unstructured":"Strassman, R. J. Human psychopharmacology of N,N-dimethyltryptamine. Behav. Brain Res. 73, 121\u2013124 (1996).","journal-title":"Behav. Brain Res."},{"key":"7403_CR53","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1016\/j.euroneuro.2016.01.005","volume":"26","author":"T Pokorny","year":"2016","unstructured":"Pokorny, T., Preller, K. H., Kraehenmann, R. & Vollenweider, F. X. Modulatory effect of the 5-HT1A agonist buspirone and the mixed non-hallucinogenic 5-HT1A\/2A agonist ergotamine on psilocybin-induced psychedelic experience. Eur. Neuropsychopharmacol. 26, 756\u2013766 (2016).","journal-title":"Eur. Neuropsychopharmacol."},{"key":"7403_CR54","doi-asserted-by":"publisher","first-page":"760671","DOI":"10.3389\/fphar.2021.760671","volume":"12","author":"J Reckweg","year":"2021","unstructured":"Reckweg, J. et al. A phase 1, dose-ranging study to assess safety and psychoactive effects of a vaporized 5-methoxy-N,N-dimethyltryptamine formulation (GH001) in healthy volunteers. Front. Pharmacol. 12, 760671 (2021).","journal-title":"Front. Pharmacol."},{"key":"7403_CR55","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1038\/sj.npp.1300203","volume":"28","author":"DA Shapiro","year":"2003","unstructured":"Shapiro, D. A. et al. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology 28, 1400\u20131411 (2003).","journal-title":"Neuropsychopharmacology"},{"key":"7403_CR56","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1038\/nmeth.4193","volume":"14","author":"SQ Zheng","year":"2017","unstructured":"Zheng, S. Q. et al. MotionCor2: anisotropic correction of beam-induced motion for improved cryo-electron microscopy. Nat. Methods 14, 331\u2013332 (2017).","journal-title":"Nat. Methods"},{"key":"7403_CR57","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/nmeth.4169","volume":"14","author":"A Punjani","year":"2017","unstructured":"Punjani, A., Rubinstein, J. L., Fleet, D. J. & Brubaker, M. A. cryoSPARC: algorithms for rapid unsupervised cryo-EM structure determination. Nat. Methods 14, 290\u2013296 (2017).","journal-title":"Nat. Methods"},{"key":"7403_CR58","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1038\/s41592-020-00990-8","volume":"17","author":"A Punjani","year":"2020","unstructured":"Punjani, A., Zhang, H. & Fleet, D. J. Non-uniform refinement: adaptive regularization improves single-particle cryo-EM reconstruction. Nat. Methods 17, 1214\u20131221 (2020).","journal-title":"Nat. Methods"},{"key":"7403_CR59","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1107\/S0907444910007493","volume":"66","author":"P Emsley","year":"2010","unstructured":"Emsley, P., Lohkamp, B., Scott, W. G. & Cowtan, K. Features and development of Coot. Acta Crystallogr. D Biol. Crystallogr. 66, 486\u2013501 (2010).","journal-title":"Acta Crystallogr. D Biol. Crystallogr."},{"key":"7403_CR60","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1107\/S2059798319011471","volume":"75","author":"D Liebschner","year":"2019","unstructured":"Liebschner, D. et al. Macromolecular structure determination using X-rays, neutrons and electrons: recent developments in Phenix. Acta Crystallogr. D Struct. Biol. 75, 861\u2013877 (2019).","journal-title":"Acta Crystallogr. D Struct. Biol."},{"key":"7403_CR61","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1107\/S2059798321009475","volume":"77","author":"K Yamashita","year":"2021","unstructured":"Yamashita, K., Palmer, C. M., Burnley, T. & Murshudov, G. N. Cryo-EM single-particle structure refinement and map calculation using Servalcat. Acta Crystallogr. D Struct. Biol. 77, 1282\u20131291 (2021).","journal-title":"Acta Crystallogr. D Struct. Biol."},{"key":"7403_CR62","unstructured":"The PyMOL Molecular Graphics System v.2.0 (Schr\u00f6dinger, 2017)."},{"key":"7403_CR63","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1038\/nsmb.3014","volume":"22","author":"WK Kroeze","year":"2015","unstructured":"Kroeze, W. K. et al. PRESTO-Tango as an open-source resource for interrogation of the druggable human GPCRome. Nat. Struct. Mol. Biol. 22, 362\u2013369 (2015).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"7403_CR64","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1021\/acschemneuro.7b00320","volume":"9","author":"A Henke","year":"2018","unstructured":"Henke, A. et al. Toward serotonin fluorescent false neurotransmitters: development of fluorescent dual serotonin and vesicular monoamine transporter substrates for visualizing serotonin neurons. ACS Chem. Neurosci. 9, 925\u2013934 (2018).","journal-title":"ACS Chem. Neurosci."},{"key":"7403_CR65","doi-asserted-by":"crossref","unstructured":"Rodr\u0131\u0301guez, P. et al. A single administration of the atypical psychedelic ibogaine or its metabolite noribogaine induces an antidepressant-like effect in rats. ACS Chem. Neurosci. 11, 1661\u20131672 (2020).","DOI":"10.1021\/acschemneuro.0c00152"}],"container-title":["Nature"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41586-024-07403-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41586-024-07403-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41586-024-07403-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,8]],"date-time":"2024-06-08T12:02:58Z","timestamp":1717848178000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41586-024-07403-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,8]]},"references-count":65,"journal-issue":{"issue":"8015","published-print":{"date-parts":[[2024,6,6]]}},"alternative-id":["7403"],"URL":"https:\/\/doi.org\/10.1038\/s41586-024-07403-2","relation":{},"ISSN":["0028-0836","1476-4687"],"issn-type":[{"value":"0028-0836","type":"print"},{"value":"1476-4687","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,8]]},"assertion":[{"value":"14 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare the following competing financial interests: D.S. and A.C.K. are co-founders of Gilgamesh Pharmaceuticals and Kures. M.\u2009J.\u2009Cunningham is a co-founder of Gilgamesh Pharmaceuticals. A.L.W., D.L., I.C.S., L.F.P., S.J.R., D.S. and D.W. are inventors on a patent application related to the featured compound class. D.W. has consulted for Otsuka Pharmaceutical, Longboard Pharmaceuticals and Ocean Bio on the design of psychedelic-based therapeutics. None of the companies listed herein contributed to the funding or experimental design. All other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}